-+ 0.00%
-+ 0.00%
-+ 0.00%

FibroBiologics Expands Its Wound Care Platform To Treat Patients With Acute, Chronic Burn Injuries

Benzinga·03/12/2026 12:47:55
Listen to the news

FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using proprietary fibroblast spheroid technology, today announced the expansion of its wound care platform into the treatment of patients with acute and chronic burn injuries.

Building on its investigational fibroblast spheroid-based programs in chronic wound healing, FibroBiologics is applying the same core technology to address the significant unmet medical needs in burn care, where current standards of care often result in prolonged healing, multiple procedures, and substantial scarring.